This aligns to DR Gourlays roadmap to mitigate Cortisol and if evidenced through the Trial will put ACW in medical breakthrough territory.
Mind you the data,in the small trial, already points to this out one which is likely to be validated in the current extended trial.
Current SP provides outstanding risk based opportunity with this paper supporting that thesis.
This aligns to DR Gourlays roadmap to mitigate Cortisol and if...
Add to My Watchlist
What is My Watchlist?
 (20min delay)
|
|||||
|
Last
2.5¢ |
Change
-0.001(2.00%) |
Mkt cap ! $77.84M | |||
| Open | High | Low | Value | Volume |
| 2.4¢ | 2.5¢ | 2.4¢ | $26.17K | 1.089M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 16 | 3662851 | 2.4¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 2.5¢ | 1074084 | 5 |
View Market Depth
| Last trade - 10.55am 31/07/2025 (20 minute delay) ? |
| ACW (ASX) Chart |